Stability of IPs [GxP / QC / QA]

posted by ElMaestro  – Denmark, 2020-06-10 20:17 (971 d 09:52 ago) – Posting: # 21525
Views: 1,431

Hello Loky do,

❝ To what extent an increase in humidity affects Investigational products stability? if the humidity of the drug store reached > 70% what will be the accepted measures taken to prove that no impact has occurred to samples?


In Europe, this would often be a question for the manufacturer or release officer: Details of the temperature excursions can be shared and then the QP will make a decision. There is some subjective judgment involved unless the parties sit on actual stability evidence covering (=qualifying or disqualifying) the excursions. Depending on amounts available, there is also the opportunity to subject the IMP to new testing, i.e. production of a new CoA and subsequent release. In that case the testing is done with all the bells and whistles.

If you are working at a CRO and the temperature excursion happened there, then you are most likely not in a position to judge it on your own.

The above applies only to the regulated areas I know of. It is my impression that you are in Egypt and I do not know how things work if the phenomenon happened there.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
20 visitors (1 registered, 19 guests [including 10 identified bots]).
Forum time: 05:10 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5